Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Lundbeck partners with IBM Watson on drug research

The deal will also see it set up a new real world evidence platform

Lundbeck headquarters 

Lundbeck has become the latest pharma company to partner with IBM Watson Health, with a deal to speed up its development of psychiatric and neurological treatments.

The Danish firm hopes that adding its drug research know-how to IBM's cognitive computing and analytics will help it develop innovative new medicines.

Starting with projects in schizophrenia and Parkinson's disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications.

Anders Gersel Pedersen, R&D executive VP at Lundbeck, said: “We strive to develop treatments that affect the underlying biological mechanisms of psychiatric and neurological disorders rather than treating only symptoms. 

“By combining our expertise in brain research with IBM's cognitive computer technology, we expect to improve our foundation for this work, so we can develop new and improved treatments for the 425 million people who suffer from the psychiatric and neurological disorders which Lundbeck focuses on.”

Moving beyond drug development and into market access and regulatory considerations, the collaboration will also see Lundbeck set up a new real world evidence and advanced analytics platform.

The platform will provide Lundbeck with access both Watson technology and clinical data in the form of millions of anonymised patient records via the Watson health Cloud.

The deal also allows for the pharma company to use Watson technologies across other Lundbeck data - whether clinical or not - and health insurance claims data.

“IBM can help create data-driven hypotheses based on Lundbeck's questions, which can then be used in further research on fighting psychiatric and neurological disorders,” Pedersen added.

After making a billion-dollar investment in Watson's health capabilities, the last year has seen IBM strike deals with the likes of Pfizer, GlaxoSmithKline, Otsuka and Celgene.

10th February 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...
Spotlight interview: 15 minutes on Independent Medical Education
Celeste Kolanko, Managing Director of Liberum, OPEN Health takes 15 minutes to answer some key questions on independent medical education....

Infographics